药物基因组学研究近展

牵牛花

1997年6月28日金赛特（巴黎）可伯特实验室宣布成立世界上第一个独特的基因与制药公司，研究基因变异所致的不同疾病对药物的不同反应，并在此基础上研制出新药或新的用药方法，这一新概念被称为药物基因组学。 药物基因组学可以说是基因功能学与分子药理学的有机结合，在很多方面这种结合是非常必要的。药物基因组学区别于一般意义上的基因学，它不是以发现人体基因组基因为主要目的，而是相对简单地运用已知的基因理论改善病人的治疗。药物基因组学以药物效应及安全性为目标，研究各种基因突变与药效及安全性的关系。正因为药物基因组学是研究基因序列变异及其对药物不同反应的科学，所以它是研究高效、特效药物的重要途径，通过它为患者或者特定人群寻找合适的药物。自药物基因组学概念出现至今，大量的研究力量投身于该领域，并且有了不少可观的进展。 为此，CMBI特准备了关于药物基因组学研究近展的特别报导，供大家参考。更多的文献，请用相关关键词通过CMBI文献查询获取。


--------------------------------------------------------------------------------

Toward an integrative systems toxicology

Personalized medicine-decades away

Teaching and practicing pharmacogenomics

RNAi specificity

pharmacogenomics and antirheumatic drugs

Pharmacogenomic data

Pharmacogenomic data sample collection and storage

Nucleic acid-based technologies

New technologies for high-throughput analysis

Cell-based microarrays

Cancer biomarker discovery and serum proteomic diagnostics

Application of RAGE and GECKO in cell-based target discovery screens

Homocysteine-exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy

Genomics and new targets for multiple sclerosis

Genome – Proteomics-the future of biomedicine

Gene variants in noncoding regions and their possible consequences

Gene expression profiling in the discovery, optimization and development of novel drugs

Pharmacogenomics and drug response in cardiovascular disorders

-Biomarkers

Copy number variants and pharmacogenomics

Clinical genomics data standards for pharmacogenetics and pharmacogenomics

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

β2-adrenergic receptor polymorphisms and asthma

UK Biobank

Translating RNA interference into therapies for human disease

Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies

Toward the $1000 human genome

The pharmacogenetics of coumarin therapy

The pharmacogenetics of calcineurin inhibitors

The implementation of molecular markers in colon cancer

The future of genetic and genomic medicine in health risk assessment and disease

the Emerging Use of Omic Technologies for Regulatory Non-Clinical Safety Testing

Sarcomas and pharmacogenetics

Recursive partitioning analysis of complex disease pharmacogenetic studies

Postgenomic characterization of G-protein-coupled receptors

Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis

Pharmacogenomics-a path to predictive medicine for schizophrenia

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

Pharmacogenomics and functional gastrointestinal disorders

Pharmacogenomics and drug development

Pharmacogenomics and Clinical R&D

Pharmacogenetics of folate-related drug targets in cancer treatment

Pharmacogenetics of controlled ovarian hyperstimulation

Pharmacogenetics and the concept of individualized medicine

Pharmacogenetics and anesthesiologists

Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics

pharmacogenetic impact of inflammatory genes on bladder cancer

Patients’ and physicians’ perspectives on pharmacogenetic testing

Multifactor dimensionality reduction for detecting gene–gene and gene–environment interactions in pharmacogenomics studies

method-Microarray expression technology

Large recursive partitioning analysis of complex disease pharmacogenetic studies

HIV resistance testing in the USA – a model for the application of pharmacogenomics

Genomics in multiple myeloma

Genomic profiling associated with recurrence in patients with rectal cancer

Genomic characterization of Alzheimer's disease

Genomic approaches for reconstructing gene networks

Genetic susceptibility to iatrogenic malignancy

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms

Flavin-containing monooxygenase genetic polymorphism

FDA clears Third Wave pharmacogenetic test

Expression genomics and cancer biology

emergence of a new paradigm of pharmacogenomics

design of a pharmacogenomic dose-finding study

Defining the opportunity for pharmacogenetic intervention in primary care

Pharmacogenomics of adrenoceptors

Pharmacogenomics and acquired long QT syndrome

Frequency of compound genotypes associated with β-blocker efficacy in congestive heart failure

Concordance of pharmacogenetic markers in germline and colorectal tumor DNA

Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation

Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy

Using microarrays to predict resistance to chemotherapy in cancer patients

Pharmacogenomics and stomach cancer

Bridging the divide-the need for translational informatics

Breast cancer gene expression profiling

Autonomic Nervous System Pharmacogenomics

Application of proteomic technologies to tumor analysis

An information-driven approach to pharmacogenomics

Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics

Pharmacogenomics and nicotine addiction treatment

Pharmacogenomics and drug development

Pharmacogenomics and Clinical R&D

Pharmacogenomics and antidepressant drugs

Pharmacogenomic data submissions to the FDA

Pharmacogenomic data submissions to the FDA

Pharmacogenomic data submissions to the FDA-clinical case studies

s-Development Issues and Solutions for Safe and Effective Medicines

-Priorities and standards in pharmacogenetic research